Anacetrapib Explained

Anacetrapib is a CETP inhibitor which was being developed to treat elevated cholesterol levels in an effort to prevent cardiovascular disease.^[1] In 2017 its development was abandoned by Merck.^[2]

Evidence

In 2017 REVEAL trial anacetrapib was shown to decrease the risk of repeat heart attacks in high-risk patients with previous acute coronary events.^[3]

See also

Other CETP inhibitors:

• Torcetrapib was developed by Pfizer until December 2006 but caused unacceptable increases in blood pressure and had net cardiovascular detriment.
• Dalcetrapib was developed by Hoffmann–La Roche until May 2012. It did not raise blood pressure and did raise HDL, but it showed no clinically meaningful efficacy.
• Evacetrapib was developed by Eli Lilly and Company until October 2015.

Further reading

• WO . 2007005572. Process for synthesizing a CETP inhibitor. 2007-01-11. Merck & Co. Inc.. Miller. Ross A.. Cote. Aaron S..

Notes and References

1. Gutstein DE, Krishna R, Johns D . Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction . Clinical Pharmacology & Therapeutics . 91 . 1 . 109–122 . 2012 . 10.1038/clpt.2011.271 . 22130116 . 36510986 . etal.
2. News: Merck says will not seek approval of cholesterol treatment. 18 October 2017. Reuters. 2017.
3. Filippatos. TD. Kei. A. Elisaf. MS. Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?. Diseases. 29 September 2017. 5. 4. 10.3390/diseases5040021. 28961179. 5750532. 21. free.